Pulmonary hypertension (PH) is common and may result from a number of disorders, including left heart disease, lung disease, and chronic thromboembolic disease. Pulmonary arterial hypertension (PAH) is an uncommon disease characterized by progressive remodeling of the distal pulmonary arteries, resulting in elevated pulmonary vascular resistance and, eventually, in right ventricular failure. Over the past decades, knowledge of the basic pathobiology of PAH and its natural history, prognostic indicators, and therapeutic options has exploded. A thorough evaluation of a patient is critical to correctly characterize the PH.
evaluation, characterized by an mPAP $25 mm Hg with normal pulmonary artery occlusion pressure (i.e., pulmonary capillary wedge pressure [PCWP] #15 mm Hg) and pulmonary vascular resistance (PVR) above 3 Wood units, in the absence of pulmonary parenchymal or thromboembolic disease. As shown in Table 1 , PAH may occur in isolation or in association with several clinical conditions. I d i o p a t h i c a n d h e r i t a b l e P A H . Although idiopathic pulmonary arterial hypertension (IPAH) might represent the most studied form of PAH, it corresponds to a rare presentation in which no family history of PAH or associated risk factor is present. Therefore, IPAH is only diagnosed after extensive investigation ruling out alternative diagnoses (4) .
Heritable forms of PAH include those with identified gene mutations and familial cases with or without mutations. Up to 80% of familial cases of PAH have been linked to germline mutations in the gene coding for the bone morphogenetic protein receptor type II (BMPR2), a member of the transforming growth factor (TGF)-b signaling family (6) . BMPR2 mutations have also been detected in around 20% of apparently idiopathic cases without a family history of PAH (7) . Other mutations in genes from the TGF-b family are also known to be associated with particular PAH presentations, such as comorbid hereditary hemorrhagic telangiectasia (ACVRL1, Endoglin) (8) .
Recently, mutations in the novel PAHassociated genes Caveolin 1 and KCNK3 have been described. Caveolin 1 (9) and KCNK3 (10) are not closely related to the TGF-b family, thereby providing new and different insights in terms of potential pathophysiological mechanisms and therapeutic targets. (11, 12) . More recently, benfluorex, a benzoate ester that shares structural and pharmacologic characteristics with dexfenfluramine and fenfluramine, has also been associated with the development of PAH (13) . Among other classes of drugs that may be linked to the development of PAH, dasatinib, a tyrosine kinase inhibitor, gained particular attention after a case series of drug-induced PAH was reported in chronic myelogenous leukemia patients (14) . Type I interferons have also been linked to an increased risk of developing PAH (15) .
PAH associated with connective tissue diseases. One of the most important forms of PAH is connective tissue disease (CTD)-associated PAH. CTD-associated PAH accounts for 15% to 25% of all PAH cases in worldwide registries, with systemic sclerosis and systemic lupus erythematosus as the leading causes (16, 17) . These patients have a particularly poor prognosis, with an estimated 30% 1-year mortality, compared to 15% in IPAH. It was recently suggested that implementation of a systematic screening program to allow earlier diagnosis and intervention might result in better long-term outcomes for this subgroup of PAH patients (18, 19) . Cases of reversible PAH have been reported in PAH patients with systemic lupus erythematosus and mixed CTD. prevalence of PAH in this group is estimated to be 0.5% (20, 21) , with clinical and hemodynamic presentation very similar to IPAH. Prognosis of HIVassociated PAH has improved in recent years; in the REVEAL (Registry to Evaluate Early And Long-term PAH Disease Management) registry, the survival of HIV-associated PAH was 93% at 1 year and 75% at 3 years (22) . Cases of reversible PAH have been reported in HIV patients treated with PAH drugs and highly-active antiretroviral drugs (22) . The clinical and histopathological similarities between Sch-PAH and IPAH have been recently described (26) , although Sch-PAH apparently has a more benign clinical course with a 3-year mortality of about 15% (26) . A recent case series also suggested that these patients might have a beneficial response to PAH targeted therapies (27) . P u l m o n a r y v e n o -o c c l u s i v e d i s e a s e , p u l m o n a r y c a p i l l a r y h e m a n g i o m a t o s i s , a n d p e r s i s t e n t P H o f t h e n e w b o r n . Pulmonary veno-occlusive disease (PVOD) and pulmonary capillary hemangiomatosis, rare variants within the same spectrum of disease, share some similarities with PAH, although with remarkable differences in presentation, mainly with respect to chest computed tomography findings, causal homozygous EIF2AK4 mutations in heritable cases, and clinical course (28, 29) . These entities remain closer to the PAH spectrum of disease than to any other PH group and, thus, are classified as 1 0 . Due to numerous differences with all other forms of PAH, persistent PH of the newborn has also been withdrawn from the PAH group and is classified as 1 00 (5). GROUP 2: PH DUE TO LEFT HEART DISEASE. This group encompasses the most frequent form of PH. In these patients, PH is a consequence of the elevated filling pressures of the left heart chambers transmitted backward to the pulmonary circulation. In this setting, PVR is usually normal, as is the gradient between the mPAP and the PCWP (transpulmonary gradient; <12 mm Hg) and the gradient between the diastolic pulmonary artery pressure and the PCWP (diastolic pressure gradient; <5 to 7 mm Hg). Nevertheless, in a subgroup of patients, a pre-capillary component might also be present, characterizing a mixed hemodynamic pattern (combined pre-and post-capillary PH) (30) . Further studies are necessary to assess the potential benefits and risks of PAHspecific therapy in this group. 
PATHOLOGY AND PATHOBIOLOGY OF PAH
In PAH, pulmonary vascular lesions predominantly affect the small pulmonary arteries (diameter <500 mm).
A wide array of changes can all occur in PAH, ranging from medial hypertrophy, intimal proliferative and fibrotic changes (concentric, eccentric), adventitial thickening with moderate perivascular inflammatory infiltrates (which may be more pronounced and organized in tertiary lymphoid tissue), complex lesions (plexiform, dilated lesions), and thrombotic lesions (31) (32) (33) . In contrast to PVOD, pulmonary veins are less affected in PAH (31) . Vasoconstriction/vasodilation imbalance, thrombosis, cell proliferation, and remodeling of the pulmonary arterial walls contribute to PAH pathobiology (32, 33) . Several cell types play a role in the disease, including endothelial cells, smooth muscle cells, pericytes, myofibroblasts, inflammatory cells (macrophages, dendritic cells, mast cells, T and B lymphocytes), and platelets (32) (33) (34) (35) . Pulmonary vasoconstriction has long been regarded as an early event, and excessive pulmonary vasoconstriction has been related to abnormal function or expression of potassium-channels and to endothelial dysfunction characterized by reduced production of vasodilators (nitric oxide and prostacyclin) and overproduction of vasoconstrictors (endothelin-1) (32) . These factors will increase pulmonary vascular tone and favor remodeling, and therefore represent logical pharmacological targets. Other mediators are also believed to play an important role in subsets of PAH patients, including proinflammatory cytokines (interleukin-1 and -6, tumor necrosis factor a), chemokines, serotonin, angiopoietins, bone morphogenetic proteins (BMPs), growth factors, and members of the TGF-b superfamily (32) (33) (34) (35) (36) . Proteolysis of the extracellular matrix and autoimmunity are also likely to contribute to disease pathobiology. The key role of the TGF-b superfamily in pulmonary vascular remodeling has been highlighted by cases of heritable PAH due to germline mutations of BMPR2, ACVRL1, and Endoglin (37). The products of these genes are involved in the regulation of growth, differentiation, and apoptosis of pulmonary artery endothelial and smooth muscle cells. Idiopathic and heritable PAH affect twice as many females as males, emphasizing the likely role of additional factors in the pathobiological mechanisms leading to PAH, including sexual hormones and pregnancy (37) .
NATURAL HISTORY OF PAH,

LESSONS FROM REGISTRIES
Until the end of the last century, PAH was a true orphan disease, that is, a condition affecting a few individuals and overlooked by the medical and pharmaceutical world. Although rare, a number of important recent findings have significantly improved our understanding of PAH. In 1973, the World Health Organization sponsored the first international conference on a condition that was then named which have been reviewed previously (41) . Table 2 displays a checklist of items to remember when evaluating the echocardiogram in a patient with known or suspected PH. (43) . Pulmonary vasodilator testing helps to determine who is most likely to respond to calcium-channel blocker therapy and also provides prognostic information. A positive response to pulmonary vasodilator testing should include all of the following: 1) decrease in mPAP to #40 mm Hg; 2) decrease of at least 10 mm Hg in mPAP; and 3) unchanged or increased cardiac output (43) . It is important to note that a lack of acute pulmonary vasodilator response does not signify a "nonresponder" to PAH therapies. Most PAH patients will not have a positive response to a pulmonary vasodilator challenge; however, many of these patients will respond to long-term selective PAH-specific therapy (see later section "Therapy for PAH"). Pulmonary vasodilator challenge with agents such as iNO, adenosine, and prostacyclins should not be performed in patients with evidence of significant PVH (e.g., PCWP >18 to 20 mm Hg). Furthermore, although pulmonary vasodilator testing has been used commonly in patients with "associated-PAH" such as HIV, CTD, CHD, and portopulmonary hypertension, there is less rigorous data supporting its use in these patients. There is no data supporting the use of vasodilator testing or calcium-channel blockers in patients with PH other than PAH.
Exercise testing can be very helpful in the assessment of patients with suspected or known PH because In recent years, there has been increased focus on evaluation of RV structure and function in the setting of PH, using echocardiography and CMR as the 2 primary clinical imaging modalities. Table 2 lists useful echocardiographic parameters for determining whether the RV is enlarged or dysfunctional.
RV systolic function can be evaluated using 2-dimensional images (e.g., RV fractional area chance in the apical 4-chamber view) ( Figure 3A) ; M-mode (e.g., tricuspid annular plane systolic excursion [TAPSE]) ( Figure 3B) ; and tissue Doppler imaging (e.g., RV basal free wall systolic [s 0 ] velocity at the level of the tricuspid annulus) ( Figure 3C) patients with PAH often exhibit late gadolinium enhancement at the RV insertion points ( Figure 3E ). Despite warnings and contraceptive measures to avoid pregnancy, some women with PAH will get pregnant. In these patients, termination of pregnancy should be discussed. If the patient desires to keep the pregnancy, the following steps should be followed to try to ensure the best possible outcome for the mother and child: 1) referral to a PAH specialist and high-risk obstetrician (with close collaboration between the PAH and obstetrics teams); 2) discontinue It is also important to note that acute-on-chronic RV failure in PAH is physiologically different than acute RV failure (e.g., RV myocardial infarction). Given these hemodynamic abnormalities, we advocate the following steps for the management of critically ill PAH patients: 1) consider invasive hemodynamic monitoring (e.g., pulmonary artery catheter) for diagnostic purposes to determine the hemodynamic abnormality and filling pressures present; 2) increase systemic blood pressure with drugs such as dobutamine and/or phenylephrine to achieve a systolic blood pressure >90 mm Hg; 3) optimize central venous pressure to 8 to 10 mm Hg (use IV diuretic agents, ultrafiltration, or continuous venovenous hemofiltration if necessary); 4) transfuse packed red blood cells to maintain hemoglobin >10 g/dl; 5) continue pulmonary vasodilator drugs that the patient was taking previously as an outpatient; and 6) consider prescribing iNO (typical dose ¼ 20 ppm), especially if the patient is on a ventilator, remembering to wean off slowly to avoid rebound elevations in PA pressure. If these measures fail, adding an inotropic agent to increase RV contractility can be considered. In addition, the use of short-term, percutaneous, partial ventricular support devices, such as a Tandem Heart (CardiacAssist, Inc., Pittsburgh, Pennsylvania) (inflow cannula in the RA and outflow cannula in the PA) or RV Impella catheter (Abiomed, Danvers, Massachusetts) have been described in the setting of RV failure (109, 110) . In severe cases, where there is a clear reversible cause of RV decompensation, extracorporeal life support (e.g., venoarterial extracorporeal membrane oxygenator) can be administered and can be life-saving; bilateral lung transplantation should also be considered in these cases (80) .
Most
COLLABORATIVE CARE OF THE PAH PATIENT.
Management of the PAH patient requires a multidisciplinary approach and collaboration between local care and the PH specialty center (Figure 4) . Given the delay from symptom onset to diagnosis, greater awareness in the community is required to achieve 
